Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a research report issued on Saturday.
Other equities analysts also recently issued research reports about the stock. Citigroup reaffirmed an "outperform" rating on shares of Zevra Therapeutics in a research note on Wednesday, May 14th. HC Wainwright initiated coverage on shares of Zevra Therapeutics in a research note on Wednesday, July 2nd. They set a "buy" rating and a $26.00 price target for the company. Finally, Cantor Fitzgerald raised their price target on shares of Zevra Therapeutics from $25.00 to $29.00 and gave the company an "overweight" rating in a research note on Thursday. Eight equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $23.71.
Read Our Latest Research Report on ZVRA
Zevra Therapeutics Price Performance
Shares of NASDAQ:ZVRA opened at $12.53 on Friday. The company has a market cap of $685.14 million, a price-to-earnings ratio of -6.59 and a beta of 1.97. The company has a debt-to-equity ratio of 1.46, a current ratio of 3.02 and a quick ratio of 2.93. The firm has a 50 day simple moving average of $9.06 and a 200 day simple moving average of $8.21. Zevra Therapeutics has a one year low of $5.45 and a one year high of $12.55.
Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.15. The business had revenue of $20.40 million during the quarter, compared to the consensus estimate of $16.96 million. Zevra Therapeutics had a negative net margin of 226.78% and a negative return on equity of 201.05%. During the same quarter in the prior year, the firm earned ($0.40) EPS. Research analysts predict that Zevra Therapeutics will post -1.95 earnings per share for the current fiscal year.
Institutional Trading of Zevra Therapeutics
Several hedge funds and other institutional investors have recently modified their holdings of ZVRA. Rhumbline Advisers increased its holdings in Zevra Therapeutics by 9.6% during the 1st quarter. Rhumbline Advisers now owns 74,585 shares of the company's stock worth $559,000 after acquiring an additional 6,532 shares during the period. Strs Ohio purchased a new position in Zevra Therapeutics in the 1st quarter worth approximately $125,000. Woodline Partners LP grew its stake in Zevra Therapeutics by 11.5% in the 1st quarter. Woodline Partners LP now owns 4,615,625 shares of the company's stock worth $34,571,000 after buying an additional 476,032 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Zevra Therapeutics by 6.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,761 shares of the company's stock worth $238,000 after buying an additional 1,812 shares in the last quarter. Finally, Retirement Planning Co of New England Inc. grew its stake in Zevra Therapeutics by 6.9% in the 1st quarter. Retirement Planning Co of New England Inc. now owns 550,180 shares of the company's stock worth $4,121,000 after buying an additional 35,348 shares in the last quarter. Institutional investors own 35.03% of the company's stock.
Zevra Therapeutics Company Profile
(
Get Free Report)
Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Zevra Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zevra Therapeutics wasn't on the list.
While Zevra Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
